201 Elliott Avenue West
United States - Map
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. It markets Omidria for use during cataract surgery or intraocular lens, or replacement surgery. The companys clinical products include OMS721 that is in Phase II clinical trials for the treatment of various complement-mediated disorders, including complement-mediated thrombotic microangiopathies; OMS824, which is in Phase II clinical trials for the treatment of CNS disorders comprising schizophrenia and Huntington's disease; and OMS103 that has completed Phase III clinical trials for use during arthroscopic procedures, such as partial meniscectomy surgery. Its clinical programs also comprise OMS405, which is in Phase II clinical trials for the treatment and prevention of addiction to substances of abuse; and OMS201 that has completed Phase I/II clinical trials for use during urological procedures, such as ureterscopy for removal of ureteral or renal stones. The companys preclinical programs also comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders, such as Parkinson's disease; OMS616 for the control of blood loss during surgery, or resulting from trauma or other hyperfibrinolytic conditions; and OMS906 for the treatment of paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. In addition, its preclinical products consist of GPR17 for the treatment of demyelinating disorders; G protein-coupled receptor platform for multiple disorders across therapeutic area; and antibody platform for the discovery of monoclonal antibodies. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.
|Omeros Corporation’s ISS Governance QuickScore as of Apr 1, 2015 is 9. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 6; Compensation: 8.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Gregory A. Demopulos M.D.,
Co-Founder, Chairman, Chief Exec. Officer and Pres
|Mr. Michael A. Jacobsen ,
Principal Financial Officer, Chief Accounting Officer, VP of Fin. and Treasurer
|Ms. Marcia S. Kelbon Esq., J.D., M.S.,
VP of Patent, Gen. Counsel and Sec.
|Dr. George A. Gaitanaris M.D., Ph.D.,
Chief Scientific Officer and VP of Science
|Dr. Kenneth M. Ferguson Ph.D.,
Chief Devel. Officer and VP of Devel.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|